Key result
Treatment with rosiglitazone for 6 months did not significantly change myocardial triglyceride content compared with placebo (-0.1% vs -0.05%) in patients with type 2 diabetes and CVD.
Why the study?
Does rosiglitazone added to existing therapy alter myocardial triglyceride content in patients with type 2 diabetes and cardiovascular disease?
RCT (n=99)
Placebo-controlled
Randomized
Does rosiglitazone added to existing therapy alter myocardial triglyceride content in patients with type 2 diabetes and cardiovascular disease?
Treatment with rosiglitazone for 6 months does not significantly affect myocardial triglyceride content or left ventricular function in patients with type 2 diabetes and cardiovascular disease.
Answers are grounded in this paper and cite their sources.
Rosiglitazone adds no benefit on myocardial triglycerides in T2D with CVD; confirms neutral effects on cardiac steatosis.
This was a nested sub-study of a randomised placebo-controlled trial of the effect of 6 months of treatment with rosiglitazone added to existing therapy on myocardial triglyceride (mTG) content in patients with type 2 diabetes (T2D) and prevalent cardiovascular disease (CVD) or at least one additional risk factor. The primary endpoint, mTG content, was measured with cardiac (1)H-magnetic resonance spectroscopy. Of the 99 randomised participants selected for the imaging sub-study, 49 (48%) had complete and interpretable spectroscopy data (age = 58 years, duration of T2D = 9.5 years; 57% women and 69% non-white). There was no significant change in mTG in either group (-0.1 ± 0.6% and -0.05 ± 0.8% respectively) and the changes in mTG were not associated with changes in left ventricular structure or function. Compared with placebo, treatment with rosiglitazone for 6 months had no discernible effect on mTG or left ventricular function in this population with long-standing diabetes and CVD.
No takes yet. Share an insight, caveat, or question.
McGavock et al. (2011) conducted an RCT in Type 2 diabetes and prevalent cardiovascular disease or at least one additional risk factor (n=99). Rosiglitazone vs. Placebo was evaluated on Myocardial triglyceride (mTG) content. Treatment with rosiglitazone for 6 months did not significantly change myocardial triglyceride content compared with placebo (-0.1% vs -0.05%) in patients with type 2 diabetes and CVD.
Synapse has enriched 10 related papers. Consider them for comparative context: